About Us
The 8th Ace Drug Discovery Summit London, UK 2027 is a premier scientific forum uniting global researchers, biotech leaders, and pharma innovators to explore the latest advancements transforming drug discovery. This two-day summit features cutting-edge sessions on AI-driven drug design, quantum computing in simulation, targeted protein degradation, RNA therapeutics, and sustainable medicinal chemistry. Key discussions will highlight CAR-T cell therapies, immunotherapy combinations, bioinformatics, and nanomedicine, reflecting the evolving landscape of pharmaceutical R&D. Attendees will gain actionable insights into emerging technologies, fragment-based drug design, and AI-powered screening, with a strong focus on unmet medical needs and ethical considerations. With interactive panel discussions, expert-led presentations, and exclusive business meetings, the summit fosters meaningful collaboration and knowledge exchange across the drug development spectrum. Join us to stay at the forefront of innovation and reshape the future of drug discovery and therapeutic development.
Why Attend





Solutions at ADDS
🔷Antibody Engineering
🔷Biochemistry
🔷Bio-informatics
🔷ADMUPI (Toxicology)
🔷Biomarker Validation
🔷Combinatorial Chemistry
🔷Covering Biological studies
🔷Data Management
   Technology
🔷Digital Imaging Technology
🔷DNA & RNA Analysis
🔷DNA Sequencing Services
🔷Drug Discovery Technology
   Platforms
🔷Preclinical
🔷Principal Scientists
🔷Regulatory Affairs
🔷Research & Development
🔷Transgenesis Services
🔷Genomics
🔷High Throughput Screening
🔷Licensing
🔷lmaging/biomarker
🔷Imaging Tools
Who Will Attend
8th Ace Drug Discovery Summit London, UK 2027 is a premier scientific forum uniting global researchers, biotech leaders, and pharma innovators to explore the latest advancements transforming drug discovery
🔷CEO
🔷CSO
🔷Director Discovery Alliances
🔷Head of DMPK
🔷Head of Drug Design
🔷Head of Molecula Toxicology
🔷VP Target Discovery & Assessment
🔷Head of R&D Licensing
🔷Principal Scientist
🔷Director of Discovery Strategy Portfolio
🔷Director of Screening & Compound Profiling
🔷Executive Director Chemistry
🔷Head Pharmacology & Toxicology
🔷Drug Discovery R&D Executives
Speakers Panel 2026
Norman Miller
Co-Founder And CSO
| Kutanios Ltd
Â
Asif AhmedÂ
Founder And CEO |
MIRZYME THERAPEUTICS LIMITED
John Maher
CSO |
Leucid Bio
Gergely Toth
CEO & CSO |
Cantabio Pharmaceuticals
Mark Eccleston
CEO | ValiRx
ARIJITÂ PATRA
Senior Principal Scientist |
UCB
Mikko Turunen
Founder, CSO |
RNatives Inc.
Sanjib Bhakta
Professor of Molecular Microbiology And Biochemistry |
UCL And Birkbeck, University of London
Kraiem Merabet Manel
CDO | SKYMAB BIOTHERAPEUTICS
Adele Rowley
Chief Scientific Officer | Mironid
Patrizia Anna d’Alessio
CEO |
 AISA Therapeutics
Maria Carmen Visus Miguel
Senior Director R&D Operations | AOP HEALTH
Philip M Arlen
CEO | Precision Biologics
Shayoni Dutta
Data Science Manager | GSK
Kayleigh Thirlwell
Senior Director | Resolution Therapeutics
Alan PALMER
CEO | Elixa Mediscience
Monica Reis
Group Leader | Resolution Therapeutics
Nahuel Villegas
CSO | Vivan Therapeutics
Duygu Dikicioglu
Associate Professor in Digital Bioprocess Engineering | University of College London
Juan Carlos Mobarec
Head Computational Structural Biology | Astrazeneca
Sara Hegy
Founder Coach and Scientist | GenX Leadership Academy
Stephen Harrison
Founder | Chiton Biosciences
Kathryn Armour
Principal Scientist | LifeArc
SONIAÂ MACIAÂ ESCALANTE
Chief Medical Officer | OneChain Immunotherapeutics
John Spencer
Professor/Director of MedChem, SDDC | Sussex Drug Discovery Centre
Darcie Mulhearn
Target Discovery Team Leader | PhoreMost
Vasiliki E Kalodimou
Director Flow Cytometry-Research and Regenerative Medicine | EUC Frankfurt Branch
Morten Grunnet
Vice President, Head of Neuroscience | Lundbeck
Alejandra Tomas
Professor of Cell Biology |
Imperial College London
Alexander Seifalian
Director/Professor of Nanotechnology & Regenerative Medicine |
Liberum Health
Jonathan Mason
Senior Research Advisor, Computational Chemistry |
Centessa Pharmaceuticals
Jose L Lanciego
Senior Scientist |
Center for Applied Medical Research (CIMA) University of Navarra
Speakers Panal 2026
Michael Watts
Associate Chief Clinical Informatics Officer | University Hospitals Derby And Burton NHS Trust
Vlad Anisimov
Data Science Director |
Amgen
Amer Alghabban
RDQ Inspection Management | Bristol Myers Squibb (BMS)
Lara Bloom
CEO & President | The Ehlers-Danlos Society
Chloe Citalois
Clinical Research Associate (Site Manager) | Independent
Sam Whatling
Director Clinical QA |
Autolus
Aldir Medeiros Filho
Clinical Data Scientist |Independent
Sridevi Nagarajan
Strategy Consultant | Ayusarogya
Puja Myles
Director, Clinical Practice Research Datalink | Medicines and Healthcare products Regulatory Agency
Carolina Narvaez
Patient Safety & Pharmacovigilance Global Expert, Former Head of Patient Safety, Novartis | N.A.
Nika Zigante
Clinical Supply Specialist | MEIRAGTX LIMITED
Sarah Deeley
Director, Country and Site Operations | Biogen
Arunesh Sil
UK &IE Medical Head for Transplant | Sanofi
Lavita Menezes
Director, Clinical Operations | Silence Therapeutics
Wiktor Majewski
Central Statistical Monitor | GSK
Barry Daly
Â
Sara Hegy
Founder Coach and Scientist | GenX Leadership Academy
Daizy Moumi
Associate Director of Clinical Operations | Complement Therapeutics
Svetlana Karova
Manager, Clinical Risk and Analytics | Alnylam Pharmaceuticals
HEND ABDELHAKIM
Assisant Professor , Pharmaceutical Scientist | UCL , Gustoceutics
Meelis Lootus
CEO | Tehistark OÜ
Lorelle Brownlee
Co-Founder | Composed Health
Martina Barcaroli
Global Senior Study Manager | Angelini Pharma
Madjlessi Gabrielle
International Clinical Operation Lead | Servier
Mark Sweeney
PhD Candidate | ServierImperial College LondonÂ
Sanjeev Srivastav
Signal Management Lead | BioNTech
Ilves Sanna
Head of Pharmacy Clinical Trials & Aseptic Services | The Royal Marsden Hospital
Maryna Todoriuk, MPharm, BBA
Founder | CL Group
Our Sponsors
Attendee Breakdown
Attendee Demographics
Conference Themes
14th April
AI-Enabled Discovery in Small Molecules
Computational Target Discovery and Protein Design
Deep Learning for ADCs and Next-Generation Design
 PK/PD Modelling in Early Drug Discovery Programs
Drug discovery and development for rare genetic disorders
AI in Drug Discovery: From Concept to Implementation
Future Perspectives for AI in the Drug Discovery
15th April
   Next-Generation Gene Therapy for NeurologicalÂ
Genomic Targets, Biomarkers and Targeted Therapies
MRNA Therapeutics: From Discovery to Clinical Translation
Predictive Toxicology for Safer Early Drug Development
 AI-Driven Target Discovery and Novel Therapeutic Strategies
Turning Scientific Discoveries into Effective Therapies
Biomarker Validation for Drug Development
Our Partners
Marriott International begins as an A&W Root Beer franchise in Washington, D.C., in May 1927, with the same core values that guide the company today. Founders J. Willard and Alice Sheets Marriott get their business started by quenching people’s thirst during the hot, muggy summers in Washington, D.C., before serving food and becoming The Hot Shoppes, and entering other lines of business. Heralding in a new era in 2016, Marriott International acquires Starwood Hotels & Resorts Worldwide creating the world’s largest hotel company. There is a celebration in New York City’s Time Square.
